In the News

August 6, 2020
Developers of generic and biosimilar medicines support diversification of the pharmaceutical supply chain and are working with policymakers to add to our significant manufacturing presence in the United States
increasing access to biosimilars act
July 2, 2020
The Biosimilars Council commends Senators Cornyn and Bennet for the introduction of the Increasing Access to Biosimilars Act.
February 24, 2020
The Council applauds the FDA’s action and continues to call on policymakers to support legislation that would require all patents for the reference biologic to be listed in the Purple Book.
February 5, 2020
CMS’ proposal for a separate preferred specialty tier is a very welcome and significant step that will encourage greater generic and biosimilar adoption for America’s patients.
biologics market
February 3, 2020
The Biosimilars Council welcomes the FTC and FDA collaboration to promote competition in the biologics markets and bolster confidence in these medicines.
October 2, 2019
The Biosimilars Council applauds bipartisan efforts in the U.S. House of Representatives that would encourage biosimilar uptake and utilization by patients in the Medicare program by aligning patient, provider and taxpayer incentives.

Recent Tweets

If the entire Affordable Care Act (#ACA) is overturned as unconstitutional, it could eliminate the Biologics Price Competition and Innovation Act (#BPCIA) and threaten the accessibility of life-saving treatments in the U.S.

Read more: https://www.washingtonpost.com/opinions/letters-to-the-editor/striking-down-obamacare-would-also-nix-generic-biologic-drugs/2020/06/28/44a4a630-b7c4-11ea-9a1d-d3db1cbe07ce_story.html

Load More...

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.

SIGN UP FOR OUR NEWSLETTER